CA2975166C - Crispr hybrid dna/rna polynucleotides and methods of use - Google Patents

Crispr hybrid dna/rna polynucleotides and methods of use Download PDF

Info

Publication number
CA2975166C
CA2975166C CA2975166A CA2975166A CA2975166C CA 2975166 C CA2975166 C CA 2975166C CA 2975166 A CA2975166 A CA 2975166A CA 2975166 A CA2975166 A CA 2975166A CA 2975166 C CA2975166 C CA 2975166C
Authority
CA
Canada
Prior art keywords
cell
class
activating
cas9
region
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2975166A
Other languages
English (en)
French (fr)
Other versions
CA2975166A1 (en
Inventor
Andrew P. May
Paul D. DONOHOUE
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Caribou Biosciences Inc
Original Assignee
Pioneer Hi Bred International Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pioneer Hi Bred International Inc filed Critical Pioneer Hi Bred International Inc
Priority to CA3060508A priority Critical patent/CA3060508C/en
Publication of CA2975166A1 publication Critical patent/CA2975166A1/en
Application granted granted Critical
Publication of CA2975166C publication Critical patent/CA2975166C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/102—Mutagenizing nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/111—General methods applicable to biologically active non-coding nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/82—Vectors or expression systems specially adapted for eukaryotic hosts for plant cells, e.g. plant artificial chromosomes (PACs)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/82—Vectors or expression systems specially adapted for eukaryotic hosts for plant cells, e.g. plant artificial chromosomes (PACs)
    • C12N15/8201—Methods for introducing genetic material into plant cells, e.g. DNA, RNA, stable or transient incorporation, tissue culture methods adapted for transformation
    • C12N15/8213—Targeted insertion of genes into the plant genome by homologous recombination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/90—Stable introduction of foreign DNA into chromosome
    • C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/90—Stable introduction of foreign DNA into chromosome
    • C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
    • C12N15/907—Stable introduction of foreign DNA into chromosome using homologous recombination in mammalian cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/22—Ribonucleases [RNase]; Deoxyribonucleases [DNase]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813—Hybridisation assays
    • C12Q1/6827—Hybridisation assays for detection of mutation or polymorphism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPR]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/50—Physical structure
    • C12N2310/53—Physical structure partially self-complementary or closed
    • C12N2310/531—Stem-loop; Hairpin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/50—Methods for regulating/modulating their activity
    • C12N2320/51—Methods for regulating/modulating their activity modulating the chemical stability, e.g. nuclease-resistance
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/50—Methods for regulating/modulating their activity
    • C12N2320/53—Methods for regulating/modulating their activity reducing unwanted side-effects
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Mycology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Analytical Chemistry (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
CA2975166A 2015-01-28 2016-01-27 Crispr hybrid dna/rna polynucleotides and methods of use Active CA2975166C (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CA3060508A CA3060508C (en) 2015-01-28 2016-01-27 Crispr hybrid dna/rna polynucleotides and methods of use

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201562108931P 2015-01-28 2015-01-28
US62/108,931 2015-01-28
US201562251548P 2015-11-05 2015-11-05
US62/251,548 2015-11-05
PCT/US2016/015145 WO2016123230A1 (en) 2015-01-28 2016-01-27 Crispr hybrid dna/rna polynucleotides and methods of use

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CA3060508A Division CA3060508C (en) 2015-01-28 2016-01-27 Crispr hybrid dna/rna polynucleotides and methods of use

Publications (2)

Publication Number Publication Date
CA2975166A1 CA2975166A1 (en) 2016-08-04
CA2975166C true CA2975166C (en) 2020-01-14

Family

ID=55361965

Family Applications (2)

Application Number Title Priority Date Filing Date
CA2975166A Active CA2975166C (en) 2015-01-28 2016-01-27 Crispr hybrid dna/rna polynucleotides and methods of use
CA3060508A Active CA3060508C (en) 2015-01-28 2016-01-27 Crispr hybrid dna/rna polynucleotides and methods of use

Family Applications After (1)

Application Number Title Priority Date Filing Date
CA3060508A Active CA3060508C (en) 2015-01-28 2016-01-27 Crispr hybrid dna/rna polynucleotides and methods of use

Country Status (27)

Country Link
US (11) US9650617B2 (enExample)
EP (2) EP4257690A3 (enExample)
JP (2) JP6835726B2 (enExample)
KR (4) KR20220159498A (enExample)
CN (2) CN111518811A (enExample)
AU (3) AU2016211517B2 (enExample)
BR (1) BR112017016080B1 (enExample)
CA (2) CA2975166C (enExample)
DK (1) DK3250691T5 (enExample)
ES (1) ES2955957T3 (enExample)
FI (1) FI3250691T3 (enExample)
GB (1) GB2550745A (enExample)
HR (1) HRP20231022T1 (enExample)
HU (1) HUE063813T2 (enExample)
IL (4) IL288263B (enExample)
LT (1) LT3250691T (enExample)
MX (2) MX2017009506A (enExample)
NZ (1) NZ733702A (enExample)
PL (1) PL3250691T3 (enExample)
PT (1) PT3250691T (enExample)
RS (1) RS64527B1 (enExample)
RU (1) RU2713328C2 (enExample)
SG (3) SG10201804715WA (enExample)
SI (1) SI3250691T1 (enExample)
SM (1) SMT202300341T1 (enExample)
WO (1) WO2016123230A1 (enExample)
ZA (2) ZA201705174B (enExample)

Families Citing this family (159)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112013024337A2 (pt) 2011-03-23 2017-09-26 Du Pont locus de traço transgênico complexo em uma planta, planta ou semente, método para produzir em uma planta um locus de traço transgênico complexo e construto de expressão
EP2734621B1 (en) 2011-07-22 2019-09-04 President and Fellows of Harvard College Evaluation and improvement of nuclease cleavage specificity
IL289396B2 (en) 2013-03-15 2023-12-01 The General Hospital Coporation Using truncated guide rnas (tru-grnas) to increase specificity for rna-guided genome editing
US10760064B2 (en) 2013-03-15 2020-09-01 The General Hospital Corporation RNA-guided targeting of genetic and epigenomic regulatory proteins to specific genomic loci
CA2908697C (en) 2013-04-16 2023-12-12 Regeneron Pharmaceuticals, Inc. Targeted modification of rat genome
US9163284B2 (en) 2013-08-09 2015-10-20 President And Fellows Of Harvard College Methods for identifying a target site of a Cas9 nuclease
MX363842B (es) 2013-08-22 2019-04-05 Du Pont Métodos para producir modificaciones genéticas en un genoma vegetal sin incorporar un marcador transgénico seleccionable, y composiciones de éstas.
US9359599B2 (en) 2013-08-22 2016-06-07 President And Fellows Of Harvard College Engineered transcription activator-like effector (TALE) domains and uses thereof
US9526784B2 (en) 2013-09-06 2016-12-27 President And Fellows Of Harvard College Delivery system for functional nucleases
US9322037B2 (en) 2013-09-06 2016-04-26 President And Fellows Of Harvard College Cas9-FokI fusion proteins and uses thereof
US9340800B2 (en) 2013-09-06 2016-05-17 President And Fellows Of Harvard College Extended DNA-sensing GRNAS
SG10201700961TA (en) 2013-12-11 2017-04-27 Regeneron Pharma Methods and compositions for the targeted modification of a genome
US20150165054A1 (en) 2013-12-12 2015-06-18 President And Fellows Of Harvard College Methods for correcting caspase-9 point mutations
CA2956224A1 (en) 2014-07-30 2016-02-11 President And Fellows Of Harvard College Cas9 proteins including ligand-dependent inteins
CA2956487A1 (en) 2014-09-12 2016-03-17 E. I. Du Pont De Nemours And Company Generation of site-specific-integration sites for complex trait loci in corn and soybean, and methods of use
EP3204496A1 (en) 2014-10-10 2017-08-16 Editas Medicine, Inc. Compositions and methods for promoting homology directed repair
GB201418965D0 (enExample) 2014-10-24 2014-12-10 Ospedale San Raffaele And Fond Telethon
US11680268B2 (en) 2014-11-07 2023-06-20 Editas Medicine, Inc. Methods for improving CRISPR/Cas-mediated genome-editing
LT3250691T (lt) 2015-01-28 2023-09-11 Caribou Biosciences, Inc. Crispr hibridiniai dnr/rnr polinukleotidai ir naudojimo būdai
US10450576B2 (en) 2015-03-27 2019-10-22 E I Du Pont De Nemours And Company Soybean U6 small nuclear RNA gene promoters and their use in constitutive expression of small RNA genes in plants
GB201506509D0 (en) 2015-04-16 2015-06-03 Univ Wageningen Nuclease-mediated genome editing
CA2986310A1 (en) 2015-05-11 2016-11-17 Editas Medicine, Inc. Optimized crispr/cas9 systems and methods for gene editing in stem cells
WO2016201047A1 (en) 2015-06-09 2016-12-15 Editas Medicine, Inc. Crispr/cas-related methods and compositions for improving transplantation
US20160362667A1 (en) * 2015-06-10 2016-12-15 Caribou Biosciences, Inc. CRISPR-Cas Compositions and Methods
US9790490B2 (en) * 2015-06-18 2017-10-17 The Broad Institute Inc. CRISPR enzymes and systems
US10648020B2 (en) 2015-06-18 2020-05-12 The Broad Institute, Inc. CRISPR enzymes and systems
US11279928B2 (en) 2015-06-29 2022-03-22 Massachusetts Institute Of Technology Compositions comprising nucleic acids and methods of using the same
US11414657B2 (en) 2015-06-29 2022-08-16 Ionis Pharmaceuticals, Inc. Modified CRISPR RNA and modified single CRISPR RNA and uses thereof
US9926546B2 (en) 2015-08-28 2018-03-27 The General Hospital Corporation Engineered CRISPR-Cas9 nucleases
US9512446B1 (en) 2015-08-28 2016-12-06 The General Hospital Corporation Engineered CRISPR-Cas9 nucleases
EP3786294A1 (en) 2015-09-24 2021-03-03 Editas Medicine, Inc. Use of exonucleases to improve crispr/cas-mediated genome editing
WO2017070598A1 (en) 2015-10-23 2017-04-27 Caribou Biosciences, Inc. Engineered crispr class 2 cross-type nucleic-acid targeting nucleic acids
EP4434589A3 (en) 2015-10-23 2025-05-14 President and Fellows of Harvard College Evolved cas9 proteins for gene editing
RU2018117360A (ru) * 2015-12-04 2020-01-09 Карибо Биосайенсиз, Инк. Сконструированные нуклеиновые кислоты, нацеленные на нуклеиновую кислоту
US9988624B2 (en) 2015-12-07 2018-06-05 Zymergen Inc. Microbial strain improvement by a HTP genomic engineering platform
EP3871695A1 (en) 2015-12-07 2021-09-01 Arc Bio, LLC Methods and compositions for the making and using of guide nucleic acids
US11208649B2 (en) 2015-12-07 2021-12-28 Zymergen Inc. HTP genomic engineering platform
KR20180084756A (ko) 2015-12-07 2018-07-25 지머젠 인코포레이티드 코리네박테리움 글루타미컴으로부터의 프로모터
WO2017136794A1 (en) 2016-02-03 2017-08-10 Massachusetts Institute Of Technology Structure-guided chemical modification of guide rna and its applications
US9896696B2 (en) * 2016-02-15 2018-02-20 Benson Hill Biosystems, Inc. Compositions and methods for modifying genomes
US11597924B2 (en) 2016-03-25 2023-03-07 Editas Medicine, Inc. Genome editing systems comprising repair-modulating enzyme molecules and methods of their use
WO2017180694A1 (en) 2016-04-13 2017-10-19 Editas Medicine, Inc. Cas9 fusion molecules gene editing systems, and methods of use thereof
KR20260004568A (ko) 2016-04-19 2026-01-08 더 브로드 인스티튜트, 인코퍼레이티드 신규한 crispr 효소 및 시스템
CN106244591A (zh) * 2016-08-23 2016-12-21 苏州吉玛基因股份有限公司 修饰crRNA在CRISPR/Cpf1基因编辑系统中的应用
JP2019517261A (ja) 2016-06-01 2019-06-24 カーヴェーエス ザート ソシエタス・ヨーロピアＫｗｓ Ｓａａｔ Ｓｅ ゲノム操作のためのハイブリッド核酸配列
US10767175B2 (en) 2016-06-08 2020-09-08 Agilent Technologies, Inc. High specificity genome editing using chemically modified guide RNAs
KR102345899B1 (ko) 2016-06-30 2021-12-31 지머젠 인코포레이티드 박테리아 헤모글로빈 라이브러리를 생성하는 방법 및 이의 용도
JP2019519241A (ja) 2016-06-30 2019-07-11 ザイマージェン インコーポレイテッド グルコース透過酵素ライブラリーを生成するための方法およびその使用
WO2018009822A1 (en) * 2016-07-08 2018-01-11 Ohio State Innovation Foundation Modified nucleic acids, hybrid guide rnas, and uses thereof
JP7231935B2 (ja) 2016-08-03 2023-03-08 プレジデント アンド フェローズ オブ ハーバード カレッジ アデノシン核酸塩基編集因子およびそれらの使用
US11661590B2 (en) 2016-08-09 2023-05-30 President And Fellows Of Harvard College Programmable CAS9-recombinase fusion proteins and uses thereof
WO2018031950A1 (en) 2016-08-12 2018-02-15 Caribou Biosciences, Inc. Protein engineering methods
WO2018034554A1 (ko) * 2016-08-19 2018-02-22 주식회사 툴젠 인위적으로 조작된 신생혈관형성 조절 시스템
WO2018039438A1 (en) 2016-08-24 2018-03-01 President And Fellows Of Harvard College Incorporation of unnatural amino acids into proteins using base editing
CA3034931A1 (en) 2016-09-23 2018-03-29 Board Of Trustees Of Southern Illinois University Tuning crispr/cas9 activity with chemically modified nucleotide substitutions
US11242542B2 (en) 2016-10-07 2022-02-08 Integrated Dna Technologies, Inc. S. pyogenes Cas9 mutant genes and polypeptides encoded by same
CN110462034A (zh) 2016-10-07 2019-11-15 综合Dna技术公司 化脓链球菌cas9突变基因和由其编码的多肽
AU2017342543B2 (en) 2016-10-14 2024-06-27 President And Fellows Of Harvard College AAV delivery of nucleobase editors
US20180282722A1 (en) * 2016-11-21 2018-10-04 Massachusetts Institute Of Technology Chimeric DNA:RNA Guide for High Accuracy Cas9 Genome Editing
JP2019535287A (ja) 2016-11-22 2019-12-12 インテグレイテツド・デイー・エヌ・エイ・テクノロジーズ・インコーポレイテツド Ｃｒｉｓｐｒ／ｃｐｆ１システム及び方法
US9816093B1 (en) * 2016-12-06 2017-11-14 Caribou Biosciences, Inc. Engineered nucleic acid-targeting nucleic acids
WO2018111947A1 (en) 2016-12-12 2018-06-21 Integrated Dna Technologies, Inc. Genome editing enhancement
WO2018119010A1 (en) 2016-12-19 2018-06-28 Editas Medicine, Inc. Assessing nuclease cleavage
WO2018119359A1 (en) 2016-12-23 2018-06-28 President And Fellows Of Harvard College Editing of ccr5 receptor gene to protect against hiv infection
US20190382751A1 (en) * 2016-12-28 2019-12-19 Ionis Pharmaceuticals, Inc. Modified crispr rna and uses thereof
WO2018129368A2 (en) 2017-01-06 2018-07-12 Editas Medicine, Inc. Methods of assessing nuclease cleavage
DK3574101T5 (da) * 2017-01-30 2024-09-02 Kws Saat Se & Co Kgaa Reparationsskabelonbinding til endonukleaser til genommodifikation
CN110662556A (zh) 2017-03-09 2020-01-07 哈佛大学的校长及成员们 癌症疫苗
US11898179B2 (en) 2017-03-09 2024-02-13 President And Fellows Of Harvard College Suppression of pain by gene editing
JP2020510439A (ja) 2017-03-10 2020-04-09 プレジデント アンド フェローズ オブ ハーバード カレッジ シトシンからグアニンへの塩基編集因子
WO2018176009A1 (en) 2017-03-23 2018-09-27 President And Fellows Of Harvard College Nucleobase editors comprising nucleic acid programmable dna binding proteins
WO2018183403A1 (en) 2017-03-28 2018-10-04 Caribou Biosciences, Inc. Crispr-associated (cas) protein
EP3615672A1 (en) 2017-04-28 2020-03-04 Editas Medicine, Inc. Methods and systems for analyzing guide rna molecules
US11560566B2 (en) 2017-05-12 2023-01-24 President And Fellows Of Harvard College Aptazyme-embedded guide RNAs for use with CRISPR-Cas9 in genome editing and transcriptional activation
US11603544B2 (en) 2017-06-05 2023-03-14 Fred Hutchinson Cancer Center Genomic safe harbors for genetic therapies in human stem cells and engineered nanoparticles to provide targeted genetic therapies
CN108977442B (zh) * 2017-06-05 2023-01-06 广州市锐博生物科技有限公司 用于dna编辑的系统及其应用
WO2018226900A2 (en) 2017-06-06 2018-12-13 Zymergen Inc. A htp genomic engineering platform for improving fungal strains
EP3878961A1 (en) 2017-06-06 2021-09-15 Zymergen, Inc. A htp genomic engineering platform for improving escherichia coli
AU2018279112B2 (en) * 2017-06-07 2024-11-07 Arc Bio, Llc Creation and use of guide nucleic acids
EP3635104A1 (en) 2017-06-09 2020-04-15 Editas Medicine, Inc. Engineered cas9 nucleases
CA3065326A1 (en) 2017-06-14 2018-12-20 Wisconsin Alumni Research Foundation Modified guide rnas, crispr-ribonucleotprotein complexes and methods of use
US11584955B2 (en) * 2017-07-14 2023-02-21 Shanghai Tolo Biotechnology Company Limited Application of Cas protein, method for detecting target nucleic acid molecule and kit
WO2019014564A1 (en) 2017-07-14 2019-01-17 Editas Medicine, Inc. SYSTEMS AND METHODS OF TARGETED INTEGRATION AND GENOME EDITING AND DETECTION THEREOF WITH INTEGRATED PRIMING SITES
CN107488710B (zh) 2017-07-14 2020-09-22 上海吐露港生物科技有限公司 一种Cas蛋白的用途及靶标核酸分子的检测方法和试剂盒
US11732274B2 (en) 2017-07-28 2023-08-22 President And Fellows Of Harvard College Methods and compositions for evolving base editors using phage-assisted continuous evolution (PACE)
US10316324B2 (en) 2017-08-09 2019-06-11 Benson Hill Biosystems, Inc. Compositions and methods for modifying genomes
WO2019139645A2 (en) 2017-08-30 2019-07-18 President And Fellows Of Harvard College High efficiency base editors comprising gam
WO2019046540A1 (en) 2017-08-31 2019-03-07 New York Genome Center, Inc. METHODS AND COMPOSITIONS COMPRISING CRISPR-CPF1 AND APPROVED GUIDING CRISPR RNAES FOR PROGRAMMABLE GENOMIC DELETIONS
KR20200121782A (ko) 2017-10-16 2020-10-26 더 브로드 인스티튜트, 인코퍼레이티드 아데노신 염기 편집제의 용도
JP7423520B2 (ja) 2017-11-16 2024-01-29 アストラゼネカ・アクチエボラーグ Ｃａｓ９ベースノックイン方針の効力を改善するための組成物及び方法
US20210002609A1 (en) 2017-12-05 2021-01-07 Caribou Biosciences, Inc. Modified lymphocytes
JP2021506814A (ja) 2017-12-15 2021-02-22 デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド 安定化ペプチドによって介在される標的タンパク質の分解
US12406749B2 (en) 2017-12-15 2025-09-02 The Broad Institute, Inc. Systems and methods for predicting repair outcomes in genetic engineering
WO2019147743A1 (en) * 2018-01-26 2019-08-01 Massachusetts Institute Of Technology Structure-guided chemical modification of guide rna and its applications
WO2019152941A1 (en) 2018-02-05 2019-08-08 Caribou Biosciences, Inc. Engineered gut microbes for reduction of reactivation of detoxified drugs
WO2019165168A1 (en) 2018-02-23 2019-08-29 Pioneer Hi-Bred International, Inc. Novel cas9 orthologs
WO2019173248A1 (en) 2018-03-07 2019-09-12 Caribou Biosciences, Inc. Engineered nucleic acid-targeting nucleic acids
CN112334577B (zh) 2018-04-19 2023-10-17 加利福尼亚大学董事会 用于基因编辑的组合物和方法
CN112654710A (zh) 2018-05-16 2021-04-13 辛瑟高公司 用于指导rna设计和使用的方法和系统
US12157760B2 (en) 2018-05-23 2024-12-03 The Broad Institute, Inc. Base editors and uses thereof
US12227776B2 (en) 2018-06-13 2025-02-18 Caribou Biosciences, Inc. Engineered cascade components and cascade complexes
IL278106B2 (en) * 2018-06-13 2025-02-01 Caribou Biosciences Inc Engineered CASCADE Components and CASCADE Complexes
US10227576B1 (en) 2018-06-13 2019-03-12 Caribou Biosciences, Inc. Engineered cascade components and cascade complexes
AU2019291918B2 (en) 2018-06-29 2025-06-12 Editas Medicine, Inc. Synthetic guide molecules, compositions and methods relating thereto
US12522807B2 (en) 2018-07-09 2026-01-13 The Broad Institute, Inc. RNA programmable epigenetic RNA modifiers and uses thereof
EP3847251A1 (en) 2018-09-07 2021-07-14 Astrazeneca AB Compositions and methods for improved nucleases
WO2020072390A1 (en) 2018-10-01 2020-04-09 Caribou Biosciences, Inc. Suicide module compositions and methods
KR102126573B1 (ko) 2018-10-18 2020-06-26 대한민국 CRISPR-Cas9 시스템을 이용한 유색고약버섯의 리그닌 분해효소의 유전자 편집방법 및 이의 용도
WO2020092453A1 (en) 2018-10-29 2020-05-07 The Broad Institute, Inc. Nucleobase editors comprising geocas9 and uses thereof
JP2022513408A (ja) * 2018-10-31 2022-02-07 ザイマージェン インコーポレイテッド Ｄｎａライブラリーの多重化決定論的アセンブリー
US11739320B2 (en) 2018-11-05 2023-08-29 Wisconsin Alumni Research Foundation Gene correction of Pompe disease and other autosomal recessive disorders via RNA-guided nucleases
US12365888B2 (en) 2018-12-14 2025-07-22 Pioneer Hi-Bred International, Inc. CRISPR-Cas systems for genome editing
WO2020154500A1 (en) 2019-01-23 2020-07-30 The Broad Institute, Inc. Supernegatively charged proteins and uses thereof
CN113874503A (zh) 2019-01-25 2021-12-31 辛瑟高公司 用于调节crispr活性的系统和方法
WO2020176389A1 (en) 2019-02-25 2020-09-03 Caribou Biosciences, Inc. Plasmids for gene editing
WO2020185590A1 (en) 2019-03-08 2020-09-17 Zymergen Inc. Iterative genome editing in microbes
US11053515B2 (en) 2019-03-08 2021-07-06 Zymergen Inc. Pooled genome editing in microbes
MX2021011426A (es) 2019-03-19 2022-03-11 Broad Inst Inc Metodos y composiciones para editar secuencias de nucleótidos.
US10982187B2 (en) 2019-03-26 2021-04-20 Genus Plc Bos taurus variety ‘HO840003150607238’ and methods of use thereof
WO2020214842A1 (en) 2019-04-17 2020-10-22 The Broad Institute, Inc. Adenine base editors with reduced off-target effects
US10975351B2 (en) 2019-06-17 2021-04-13 Abs Global, Inc. Bos taurus variety ‘JE840003146074527’ and methods of use therof
MX2022002642A (es) * 2019-09-05 2022-06-14 Benson Hill Inc Composiciones y metodos para modificar genomas.
US12435330B2 (en) 2019-10-10 2025-10-07 The Broad Institute, Inc. Methods and compositions for prime editing RNA
CA3161990A1 (en) 2019-11-19 2021-05-27 Benson Hill, Inc. Anti-bacterial crispr compositions and methods
EP4028521A1 (en) * 2019-12-09 2022-07-20 Caribou Biosciences, Inc. Crispr abasic restricted nucleotides and crispr accuracy via analogs
WO2021158918A1 (en) * 2020-02-05 2021-08-12 Danmarks Tekniske Universitet Compositions and methods for targeting, editing or modifying human genes
US20230087228A1 (en) * 2020-02-24 2023-03-23 The Broad Institute, Inc. Novel type iv and type i crispr-cas systems and methods of use thereof
EP4133069A2 (en) 2020-04-08 2023-02-15 Astrazeneca AB Compositions and methods for improved site-specific modification
WO2021226558A1 (en) 2020-05-08 2021-11-11 The Broad Institute, Inc. Methods and compositions for simultaneous editing of both strands of a target double-stranded nucleotide sequence
CA3177463A1 (en) * 2020-05-12 2021-11-18 Erik Joseph SONTHEIMER Modified guide rnas for crispr genome editing
JP7698715B2 (ja) * 2020-10-19 2025-06-25 カリブー・バイオサイエンシーズ・インコーポレイテッド Ｃｒｉｓｐｒ ｖ型系のためのｄｎａ含有ポリヌクレオチドおよびガイド、ならびにこれらを製造する方法および使用する方法
CN112301162B (zh) * 2020-10-22 2023-09-22 清华-伯克利深圳学院筹备办公室 同时检测dna病毒和rna病毒的病毒核酸检测方法
WO2022214522A2 (en) 2021-04-07 2022-10-13 Astrazeneca Ab Compositions and methods for site-specific modification
CA3232742A1 (en) * 2021-09-22 2023-03-30 Andrew M. Bellinger Gene editing of pcsk9 or angptl3 and compositions and methods of using same for treatment of disease
WO2023052508A2 (en) 2021-09-30 2023-04-06 Astrazeneca Ab Use of inhibitors to increase efficiency of crispr/cas insertions
CA3229091A1 (en) 2021-10-26 2023-05-04 Caribou Biosciences, Inc. Exonuclease-coupled real-time endonuclease activity assay
EP4444908A2 (en) * 2021-12-07 2024-10-16 Caribou Biosciences, Inc. A method of capturing crispr endonuclease cleavage products
EP4499829A2 (en) * 2022-03-29 2025-02-05 Accuredit Therapeutics (Suzhou) Co., Ltd. Compositions and methods for treatment of transthyretin amyloidosis
EP4508211A2 (en) * 2022-04-13 2025-02-19 Caribou Biosciences, Inc. Therapeutic applications of crispr type v systems
WO2023224327A1 (ko) * 2022-05-20 2023-11-23 한국생명공학연구원 오토라이신을 활용한 미세조류의 유전자 교정 효율을 증대시키기 위한 시스템 및 방법
EP4504764A1 (en) 2022-05-26 2025-02-12 Caribou Biosciences, Inc. Cytokine-receptor fusions for immune cell stimulation
US20250345424A1 (en) 2022-06-06 2025-11-13 Caribou Biosciences, Inc. Treatment of autoimmune diseases with engineered immune cells
EP4578945A4 (en) 2022-08-26 2025-12-17 Guangzhou Reforgene Medicine Co Ltd CRISPR-CAS13 SYSTEM AND ITS USE
EP4593871A1 (en) 2022-09-30 2025-08-06 Caribou Biosciences, Inc. Anti-ror1 chimeric antigen receptors (cars), car-nk cells and related methods
EP4584283A1 (en) 2022-11-14 2025-07-16 Caribou Biosciences, Inc. Anti-cll-1 chimeric antigen receptors, engineered cells and related methods
EP4414452A1 (en) * 2023-02-13 2024-08-14 Universidad de Granada Dual-guide rna composition for executing a single-guide rna crispr-associated system
WO2024201368A1 (en) 2023-03-29 2024-10-03 Astrazeneca Ab Use of inhibitors to increase efficiency of crispr/cas insertions
AU2024265453A1 (en) 2023-05-01 2025-09-25 Caribou Biosciences, Inc. Treatment of autoimmune diseases with bcma-targeting engineered immune cells
EP4713453A1 (en) 2023-05-15 2026-03-25 nChroma Bio, Inc. Compositions and methods for epigenetic regulation of hbv gene expression
WO2025006880A1 (en) 2023-06-29 2025-01-02 Caribou Biosciences, Inc. Diagnostic and therapeutic methods for use with ror1 antagonists
WO2025024676A1 (en) 2023-07-26 2025-01-30 Caribou Biosciences, Inc. In vitro validation methods for cd19-targeting cell therapies
WO2025026439A1 (zh) 2023-08-02 2025-02-06 广州瑞风生物科技有限公司 基因编辑系统及其应用
CN119614679A (zh) * 2023-09-14 2025-03-14 厦门大学 一款通用型核酸检测平台
WO2025064930A1 (en) * 2023-09-20 2025-03-27 Emory University Nucleic acid hairpin based triggered hydrogels and uses thereof
WO2025117745A1 (en) 2023-12-01 2025-06-05 Caribou Biosciences, Inc. Methods and compositions for improving precision of endonuclease-mediated genome editing
WO2025193609A1 (en) 2024-03-11 2025-09-18 Caribou Biosciences, Inc. Methods and compositions for cost-effective assessment of nucleic acid transcripts and isoforms in cells
WO2025193386A1 (en) 2024-03-13 2025-09-18 Caribou Biosciences, Inc. Treatment regimens for autoimmune disease with cd19-targeting engineered immune cells
WO2026024468A1 (en) 2024-07-26 2026-01-29 Caribou Biosciences, Inc. Modular linked chimeric antigen receptors
WO2026050087A1 (en) 2024-08-27 2026-03-05 Caribou Biosciences, Inc. Real-time crispr endonuclease activity assay

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4217344A (en) 1976-06-23 1980-08-12 L'oreal Compositions containing aqueous dispersions of lipid spheres
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4186183A (en) 1978-03-29 1980-01-29 The United States Of America As Represented By The Secretary Of The Army Liposome carriers in chemotherapy of leishmaniasis
US4261975A (en) 1979-09-19 1981-04-14 Merck & Co., Inc. Viral liposome particle
US4485054A (en) 1982-10-04 1984-11-27 Lipoderm Pharmaceuticals Limited Method of encapsulating biologically active materials in multilamellar lipid vesicles (MLV)
US4501728A (en) 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
US5049386A (en) 1985-01-07 1991-09-17 Syntex (U.S.A.) Inc. N-ω,(ω-1)-dialkyloxy)- and N-(ω,(ω-1)-dialkenyloxy)Alk-1-YL-N,N,N-tetrasubstituted ammonium lipids and uses therefor
US4897355A (en) 1985-01-07 1990-01-30 Syntex (U.S.A.) Inc. N[ω,(ω-1)-dialkyloxy]- and N-[ω,(ω-1)-dialkenyloxy]-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor
US4946787A (en) 1985-01-07 1990-08-07 Syntex (U.S.A.) Inc. N-(ω,(ω-1)-dialkyloxy)- and N-(ω,(ω-1)-dialkenyloxy)-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor
US4774085A (en) 1985-07-09 1988-09-27 501 Board of Regents, Univ. of Texas Pharmaceutical administration systems containing a mixture of immunomodulators
US4837028A (en) 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5264618A (en) 1990-04-19 1993-11-23 Vical, Inc. Cationic lipids for intracellular delivery of biologically active molecules
AU7979491A (en) 1990-05-03 1991-11-27 Vical, Inc. Intracellular delivery of biologically active substances by means of self-assembling lipid complexes
US7256322B2 (en) 1999-10-01 2007-08-14 Pioneer Hi-Bred International, Inc. Wuschel (WUS) Gene Homologs
AU2005210493B2 (en) 2004-02-02 2009-06-04 Pioneer Hi-Bred International, Inc. AP2 domain transcription factor ODP2 (ovule development protein 2) and methods of use
ES2719789T3 (es) * 2007-03-02 2019-07-16 Dupont Nutrition Biosci Aps Cultivos con resistencia mejorada a fagos
BR112012028805A2 (pt) 2010-05-10 2019-09-24 The Regents Of The Univ Of California E Nereus Pharmaceuticals Inc composições de endorribonuclease e métodos de uso das mesmas.
GB201122458D0 (en) 2011-12-30 2012-02-08 Univ Wageningen Modified cascade ribonucleoproteins and uses thereof
WO2013141680A1 (en) 2012-03-20 2013-09-26 Vilnius University RNA-DIRECTED DNA CLEAVAGE BY THE Cas9-crRNA COMPLEX
US9637739B2 (en) 2012-03-20 2017-05-02 Vilnius University RNA-directed DNA cleavage by the Cas9-crRNA complex
PL4289948T3 (pl) * 2012-05-25 2025-06-02 The Regents Of The University Of California Sposoby i kompozycje do modyfikacji kierowanego na rna docelowego dna i do nakierowanej na rna modulacji transkrypcji
KR20230065381A (ko) 2012-07-25 2023-05-11 더 브로드 인스티튜트, 인코퍼레이티드 유도 ｄｎａ 결합 단백질 및 게놈 교란 도구 및 이의 적용
WO2014093701A1 (en) 2012-12-12 2014-06-19 The Broad Institute, Inc. Functional genomics using crispr-cas systems, compositions, methods, knock out libraries and applications thereof
CN105658796B (zh) 2012-12-12 2021-10-26 布罗德研究所有限公司 用于序列操纵的crispr-cas组分系统、方法以及组合物
US8697359B1 (en) 2012-12-12 2014-04-15 The Broad Institute, Inc. CRISPR-Cas systems and methods for altering expression of gene products
PL2784162T3 (pl) 2012-12-12 2016-01-29 Broad Inst Inc Opracowanie systemów, metod oraz zoptymalizowanych kompozycji przewodnikowych do manipulacji sekwencyjnej
WO2014093655A2 (en) 2012-12-12 2014-06-19 The Broad Institute, Inc. Engineering and optimization of systems, methods and compositions for sequence manipulation with functional domains
CN105121648B (zh) 2012-12-12 2021-05-07 布罗德研究所有限公司 用于序列操纵的系统、方法和优化的指导组合物的工程化
PT2898075E (pt) 2012-12-12 2016-06-16 Harvard College Manipulação e otimização de sistemas, métodos e composições de enzima melhorados para manipulação de sequências
WO2014093694A1 (en) 2012-12-12 2014-06-19 The Broad Institute, Inc. Crispr-cas nickase systems, methods and compositions for sequence manipulation in eukaryotes
WO2014093622A2 (en) 2012-12-12 2014-06-19 The Broad Institute, Inc. Delivery, engineering and optimization of systems, methods and compositions for sequence manipulation and therapeutic applications
KR20170108172A (ko) 2013-03-14 2017-09-26 카리부 바이오사이언시스 인코포레이티드 핵산-표적화 핵산의 조성물 및 방법
IL289396B2 (en) * 2013-03-15 2023-12-01 The General Hospital Coporation Using truncated guide rnas (tru-grnas) to increase specificity for rna-guided genome editing
EP3674411A1 (en) * 2013-06-17 2020-07-01 The Broad Institute, Inc. Delivery, engineering and optimization of tandem guide systems, methods and compositions for sequence manipulation
MX363842B (es) * 2013-08-22 2019-04-05 Du Pont Métodos para producir modificaciones genéticas en un genoma vegetal sin incorporar un marcador transgénico seleccionable, y composiciones de éstas.
US9994831B2 (en) * 2013-12-12 2018-06-12 The Regents Of The University Of California Methods and compositions for modifying a single stranded target nucleic acid
LT3250691T (lt) 2015-01-28 2023-09-11 Caribou Biosciences, Inc. Crispr hibridiniai dnr/rnr polinukleotidai ir naudojimo būdai

Also Published As

Publication number Publication date
SG10201906513WA (en) 2019-09-27
KR102319192B1 (ko) 2021-10-28
GB201712504D0 (en) 2017-09-20
EP3250691B9 (en) 2023-08-02
SG11201705788TA (en) 2017-08-30
IL262042B (en) 2020-03-31
JP6835726B2 (ja) 2021-02-24
HUE063813T2 (hu) 2024-02-28
US20170349915A1 (en) 2017-12-07
US9771601B2 (en) 2017-09-26
ZA201705174B (en) 2018-12-19
HRP20231022T1 (hr) 2023-12-08
US9650617B2 (en) 2017-05-16
CN107810270A (zh) 2018-03-16
WO2016123230A1 (en) 2016-08-04
ZA201803945B (en) 2019-09-25
US11459588B2 (en) 2022-10-04
US11236364B2 (en) 2022-02-01
GB2550745A (en) 2017-11-29
US9580701B2 (en) 2017-02-28
KR20170126875A (ko) 2017-11-20
SG10201804715WA (en) 2018-07-30
EP3250691B1 (en) 2023-06-21
FI3250691T3 (fi) 2023-08-24
US20210371883A1 (en) 2021-12-02
AU2023202056B2 (en) 2023-05-18
AU2016211517B2 (en) 2021-05-13
US20160362668A1 (en) 2016-12-15
EP4257690A3 (en) 2024-03-27
IL273147A (en) 2020-04-30
US20170121694A1 (en) 2017-05-04
IL288263A (en) 2022-01-01
US20230193324A1 (en) 2023-06-22
US20180142263A1 (en) 2018-05-24
HK1245839A1 (en) 2018-08-31
RU2017130143A3 (enExample) 2019-07-17
PL3250691T3 (pl) 2023-11-27
CA2975166A1 (en) 2016-08-04
CA3060508A1 (en) 2016-08-04
US20250376700A1 (en) 2025-12-11
AU2021202913A1 (en) 2021-06-03
DK3250691T3 (da) 2023-09-18
RU2713328C2 (ru) 2020-02-04
AU2023202056A1 (en) 2023-05-04
IL253608B (en) 2019-02-28
BR112017016080B1 (pt) 2024-02-20
SMT202300341T1 (it) 2023-11-13
LT3250691T (lt) 2023-09-11
IL253608A0 (en) 2017-09-28
EP4257690A2 (en) 2023-10-11
US9868962B2 (en) 2018-01-16
AU2021202913B2 (en) 2023-02-16
IL288263B (en) 2022-07-01
US20200056209A1 (en) 2020-02-20
CA3060508C (en) 2023-08-29
CN111518811A (zh) 2020-08-11
PT3250691T (pt) 2023-09-25
DK3250691T5 (da) 2024-10-07
US10519468B2 (en) 2019-12-31
IL262042A (en) 2018-11-29
US9688972B2 (en) 2017-06-27
US10988781B2 (en) 2021-04-27
RU2017130143A (ru) 2019-02-28
IL273147B (en) 2021-12-01
EP3250691A1 (en) 2017-12-06
BR112017016080A2 (pt) 2018-04-03
KR20190008998A (ko) 2019-01-25
KR20220159498A (ko) 2022-12-02
JP2018503386A (ja) 2018-02-08
US20170226534A1 (en) 2017-08-10
MX2024015281A (es) 2025-02-10
MX2017009506A (es) 2017-11-02
SI3250691T1 (sl) 2023-10-30
KR20190112855A (ko) 2019-10-07
ES2955957T3 (es) 2023-12-11
AU2016211517A1 (en) 2017-08-03
US20160215300A1 (en) 2016-07-28
JP7038079B2 (ja) 2022-03-17
US20200354750A1 (en) 2020-11-12
RS64527B1 (sr) 2023-09-29
NZ733702A (en) 2022-04-29
JP2019162140A (ja) 2019-09-26

Similar Documents

Publication Publication Date Title
AU2021202913B2 (en) CRISPR hybrid DNA/RNA polynucleotides and methods of use
HK40102346A (en) Crispr hybrid dna/rna polynucleotides and methods of use
HK1245839B (en) Crispr hybrid dna/rna polynucleotides and methods of use

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20170825

EEER Examination request

Effective date: 20170825

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 9TH ANNIV.) - STANDARD

Year of fee payment: 9

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250117

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20250117